(2R,3R)-2,3-Bis(pivaloyloxy)succinic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,3R)-2,3-Bis(pivaloyloxy)succinic acid
• 英文别名: (2R,3R)-2,3-bis(2,2-dimethylpropanoyloxy)butanedioic acid
• 化学式: C₁₄H₂₂O₈
• 分子量: 318.32
• InChiKey: UFHJEZDFEHUYCR-HTQZYQBOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2R,3R)-2,3-Bis(pivaloyloxy)succinic acid 、 2-苄基甲基氨基-1-苯基-1-丙酮 生成 2-[benzyl(methyl)amino]-1-phenylpropan-1-one;(2R,3R)-2,3-bis(2,2-dimethylpropanoyloxy)butanedioic acid
  参考文献：
  名称：

  NOERI, FEDZI;OKURO, TOSIXIDEH

  摘要：

  DOI：

文献信息

• SUBSTITUTED PIPERIDINE COMPOUNDS AND THEIR USE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：US20220017517A1

  公开（公告）日：2022-01-20

  Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.

  提供以下化合物的化学式(I)、(II)、(III)和(IV)，具有促进俄雷西汀2型受体活性，或其药用可接受的盐。
• Deuterated hepatitis C protease inhibitors
  申请人：Perni B. Robert

  公开号：US20070225297A1

  公开（公告）日：2007-09-27

  A deuterated α-ketoamido steric specific compound of the formula wherein D denotes a deuterium atom on a steric specific carbon atom.

  一种氘代的α-酮氨基立体特异化合物，其化学式为其中D表示立体特异碳原子上的一个氘原子。
• Processes and intermediates for resolving piperidyl acetamide stereoisomers
  申请人：Khetani Vikram

  公开号：US20060142583A1

  公开（公告）日：2006-06-29

  Processes and intermediates for preparing 2-substituted piperidines such as 2-substituted d-threo piperidines are provided, including processes and intermediates for resolution of piperidyl acetamide stereoisomers.

  提供了制备2-取代哌啶类化合物，例如2-取代d-threo哌啶的过程和中间体，包括用于分离哌啶乙酰胺立体异构体的过程和中间体。
• Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds
  申请人：XEROX CORPORATION

  公开号：EP0667246A1

  公开（公告）日：1995-08-16

  A recording sheet which comprises a paper substrate and a material selected from the group consisting of monomeric amino acids, monomeric hydroxy acids, monomeric polycarboxyl compounds, and mixtures thereof. Another embodiment of the present invention is directed to a recording sheet which comprises a substrate and a material selected from the group consisting of monomeric amino acids, monomeric hydroxy acids, and mixtures thereof.

  一种记录纸，它包括纸基材和选自单体氨基酸、单体羟基酸、单体聚羧基化合物及其混合物组成的组的材料。本发明的另一个实施方案涉及一种记录纸，它包括基材和选自单体氨基酸、单体羟基酸及其混合物组成的组的材料。
• Process for preparing optically enriched compounds
  申请人：Vertex Pharmceuticals Incorporated

  公开号：EP2194039A1

  公开（公告）日：2010-06-09

  This invention relates to a process for preparing a compound of Formula 1 wherein: the carbon atoms alpha and beta to the carboxy group are stereocenters; R1 is independently H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; R'1 is deuterium such that the deuterium enrichment is at least 50%; R'2 is -NHR2 or -OE; R2 is H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; and E is C1-6 alkyl or benzyl; wherein the process comprises the steps of: a) forming a salt of a compound of Formula 1, and b) crystallizing said salt to give a compound of greater than 55% enantiomeric excess.

  本发明涉及一种制备式 1 化合物的工艺 其中 羧基的碳原子α和β是立体中心； R1 独立地为 H、任选取代的脂肪族、任选取代的环脂族、任选取代的芳脂族、任选取代的杂脂族或任选取代的杂芳脂族； R'1 是氘，氘富集度至少为 50%； R'2 是-NHR2 或-OE； R2 是 H、任选取代的脂肪族、任选取代的环脂族、任选取代的芳脂族、任选取代的杂脂族或任选取代的杂芳脂族；以及 E 是 C1-6 烷基或苄基； 其中该工艺包括以下步骤 a) 形成式 1 化合物的盐，和 b) 结晶所述盐，得到对映体过量率大于 55%的化合物。